TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC PINK:KANT) (“Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announce that they have entered into a definitive merger agreement in which TuHURA would acquire Kineta, including the rights to Kineta’s novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction (the “Proposed Transaction”).
Read the full article: TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. //
Source: https://www.accesswire.com/953841/tuhura-biosciences-inc-enters-into-definitive-merger-agreement-to-acquire-kineta-inc